<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">25008922</PMID><DateCompleted><Year>2015</Year><Month>01</Month><Day>22</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1098-5514</ISSN><JournalIssue CitedMedium="Internet"><Volume>88</Volume><Issue>18</Issue><PubDate><Year>2014</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Journal of virology</Title><ISOAbbreviation>J Virol</ISOAbbreviation></Journal><ArticleTitle>Virus-like particle secretion and genotype-dependent immunogenicity of dengue virus serotype 2 DNA vaccine.</ArticleTitle><Pagination><StartPage>10813</StartPage><EndPage>10830</EndPage><MedlinePgn>10813-30</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1128/JVI.00810-14</ELocationID><Abstract><AbstractText Label="UNLABELLED">Dengue virus (DENV), composed of four distinct serotypes, is the most important and rapidly emerging arthropod-borne pathogen and imposes substantial economic and public health burdens. We constructed candidate vaccines containing the DNA of five of the genotypes of dengue virus serotype 2 (DENV-2) and evaluated the immunogenicity, the neutralizing (Nt) activity of the elicited antibodies, and the protective efficacy elicited in mice immunized with the vaccine candidates. We observed a significant correlation between the level of in vitro virus-like particle secretion, the elicited antibody response, and the protective efficacy of the vaccines containing the DNA of the different DENV genotypes in immunized mice. However, higher total IgG antibody levels did not always translate into higher Nt antibodies against homologous and heterologous viruses. We also found that, in contrast to previous reports, more than 50% of total IgG targeted ectodomain III (EDIII) of the E protein, and a substantial fraction of this population was interdomain highly neutralizing flavivirus subgroup-cross-reactive antibodies, such as monoclonal antibody 1B7-5. In addition, the lack of a critical epitope(s) in the Sylvatic genotype virus recognized by interdomain antibodies could be the major cause of the poor protection of mice vaccinated with the Asian 1 genotype vaccine (pVD2-Asian 1) from lethal challenge with virus of the Sylvatic genotype. In conclusion, although the pVD2-Asian 1 vaccine was immunogenic, elicited sufficient titers of Nt antibodies against all DENV-2 genotypes, and provided 100% protection against challenge with virus of the homologous Asian 1 genotype and virus of the heterologous Cosmopolitan genotype, it is critical to monitor the potential emergence of Sylvatic genotype viruses, since vaccine candidates under development may not protect vaccinated humans from these viruses.</AbstractText><AbstractText Label="IMPORTANCE" NlmCategory="OBJECTIVE">Five genotype-specific dengue virus serotype 2 (DENV-2) DNA vaccine candidates were evaluated for their immunogenicity, homologous and heterologous neutralizing (Nt) antibody titers, and cross-genotype protection in a murine model. The immunity elicited by our prototype vaccine candidate (Asian 1 genotype strain 16681) in mice was protective against viruses of other genotypes but not against virus of the Sylvatic genotype, whose emergence and potential risk after introduction into the human population have previously been demonstrated. The underlying mechanism of a lack of protection elicited by the prototype vaccine may at least be contributed by the absence of a flavivirus subgroup-cross-reactive, highly neutralizing monoclonal antibody 1B7-5-like epitope in DENV-2 of the Sylvatic genotype. The DENV DNA vaccine directs the synthesis and assembly of virus-like particles (VLPs) and induces immune responses similar to those elicited by live-attenuated vaccines, and its flexibility permits the fast deployment of vaccine to combat emerging viruses, such as Sylvatic genotype viruses. The enhanced VLP secretion obtained by replacement of ectodomain I-II (EDI-II) of the Cosmopolitan genotype vaccine construct (VD2-Cosmopolitan) with the Asian 1 EDI-II elicited significantly higher total IgG and Nt antibody titers and suggests a novel approach to enhance the immunogenicity of the DNA vaccine. A DENV vaccine capable of eliciting protective immunity against viruses of existing and emerging genotypes should be the focus of future DENV vaccine development.</AbstractText><CopyrightInformation>Copyright &#xa9; 2014, American Society for Microbiology. All Rights Reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Galula</LastName><ForeName>Jedhan U</ForeName><Initials>JU</Initials><AffiliationInfo><Affiliation>Department of Veterinary Medicine, College of Veterinary Medicine, National Chung Hsing University, Taichung, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shen</LastName><ForeName>Wen-Fan</ForeName><Initials>WF</Initials><AffiliationInfo><Affiliation>Ph.D. Program in Microbial Genomics, National Chung Hsing University, Taichung, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chuang</LastName><ForeName>Shih-Te</ForeName><Initials>ST</Initials><AffiliationInfo><Affiliation>Department of Veterinary Medicine, College of Veterinary Medicine, National Chung Hsing University, Taichung, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chang</LastName><ForeName>Gwong-Jen J</ForeName><Initials>GJ</Initials><AffiliationInfo><Affiliation>Division of Vector-Borne Infectious Diseases, Centers for Disease Control and Prevention, Public Health Service, U.S. Department of Health and Human Services, Fort Collins, Colorado, USA gxc7@cdc.gov dychao@nchu.edu.tw.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chao</LastName><ForeName>Day-Yu</ForeName><Initials>DY</Initials><AffiliationInfo><Affiliation>Graduate Institute of Microbiology and Public Health, College of Veterinary Medicine, National Chung Hsing University, Taichung, Taiwan gxc7@cdc.gov dychao@nchu.edu.tw.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2014</Year><Month>07</Month><Day>09</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Virol</MedlineTA><NlmUniqueID>0113724</NlmUniqueID><ISSNLinking>0022-538X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D057134">Antibodies, Neutralizing</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053059">Dengue Vaccines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D019444">Vaccines, DNA</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057134" MajorTopicYN="N">Antibodies, Neutralizing</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="N">Antibodies, Viral</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D056738" MajorTopicYN="N">Cross Protection</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003429" MajorTopicYN="N">Cross Reactions</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003715" MajorTopicYN="N">Dengue</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention &amp; control</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053059" MajorTopicYN="N">Dengue Vaccines</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003716" MajorTopicYN="N">Dengue Virus</DescriptorName><QualifierName UI="Q000145" MajorTopicYN="N">classification</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005838" MajorTopicYN="N">Genotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008807" MajorTopicYN="N">Mice, Inbred BALB C</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D065288" MajorTopicYN="N">Serogroup</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019444" MajorTopicYN="N">Vaccines, DNA</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>7</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>7</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>1</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25008922</ArticleId><ArticleId IdType="pmc">PMC4178884</ArticleId><ArticleId IdType="doi">10.1128/JVI.00810-14</ArticleId><ArticleId IdType="pii">JVI.00810-14</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Kyle J, Harris E. 2008. Global spread and persistence of dengue. Annu. Rev. Microbiol. 62:71&#x2013;92. 10.1146/annurev.micro.62.081307.163005</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev.micro.62.081307.163005</ArticleId><ArticleId IdType="pubmed">18429680</ArticleId></ArticleIdList></Reference><Reference><Citation>Guzman M, Halstead S, Artsob H, Buchy P, Farrar J, Gubler D, Hunsperger E, Kroeger A, Margolis H, Mart&#xed;nez E, Nathan M, Pelegrino J, Simmons C, Yoksan S, Peeling R. 2010. Dengue: a continuing global threat. Nat. Rev. Microbiol. 8(12 Suppl):S7&#x2013;S16. 10.1038/nrmicro2460</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrmicro2460</ArticleId><ArticleId IdType="pmc">PMC4333201</ArticleId><ArticleId IdType="pubmed">21079655</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhatt S, Gething P, Brady O, Messina J, Farlow A, Moyes C, Drake J, Brownstein J, Hoen A, Sankoh O, Myers M, George D, Jaenisch T, Wint G, Simmons C, Scott T, Farrar J, Hay S. 2013. The global distribution and burden of dengue. Nature 496:504&#x2013;507. 10.1038/nature12060</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature12060</ArticleId><ArticleId IdType="pmc">PMC3651993</ArticleId><ArticleId IdType="pubmed">23563266</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilder-Smith A, Ooi E, Vasudevan S, Gubler D. 2010. Update on dengue: epidemiology, virus evolution, antiviral drugs, and vaccine development. Curr. Infect. Dis. Rep. 12:157&#x2013;164. 10.1007/s11908-010-0102-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11908-010-0102-7</ArticleId><ArticleId IdType="pubmed">21308524</ArticleId></ArticleIdList></Reference><Reference><Citation>Morrison A, Zielinski-Gutierrez E, Scott T, Rosenberg R. 2008. Defining challenges and proposing solutions for control of the virus vector Aedes aegypti. PLoS Med. 5:e68. 10.1371/journal.pmed.0050068</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pmed.0050068</ArticleId><ArticleId IdType="pmc">PMC2267811</ArticleId><ArticleId IdType="pubmed">18351798</ArticleId></ArticleIdList></Reference><Reference><Citation>Halstead SB. 2007. Dengue. Lancet 370:1644&#x2013;1652. 10.1016/S0140-6736(07)61687-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(07)61687-0</ArticleId><ArticleId IdType="pubmed">17993365</ArticleId></ArticleIdList></Reference><Reference><Citation>Chambers TJ, Hahn CS, Galler R, Rice CM. 1990. Flavivirus genome: organization, expression and replication. Annu. Rev. Microbiol. 44:649&#x2013;688. 10.1146/annurev.mi.44.100190.003245</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev.mi.44.100190.003245</ArticleId><ArticleId IdType="pubmed">2174669</ArticleId></ArticleIdList></Reference><Reference><Citation>Lindenbach BD, Rice CM. 2001. Flaviviridae: the viruses and their replication, p 991&#x2013;1110 In Knipe DM, Howley PM, Griffin DE, Lamb RA, Martin MA, Roizman B, Straus SE. (ed), Fields virology, 4th ed. Lippincott Williams &amp; Wilkins, Philadelphia, PA</Citation></Reference><Reference><Citation>Mukhopadhyay S, Kuhn R, Rossmann M. 2005. A structural perspective of the flavivirus life cycle. Nat. Rev. Microbiol. 3:13&#x2013;22. 10.1038/nrmicro1067</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrmicro1067</ArticleId><ArticleId IdType="pubmed">15608696</ArticleId></ArticleIdList></Reference><Reference><Citation>Crill WD, Roehrig JT. 2001. Monoclonal antibodies that bind to domain III of dengue virus E glycoprotein are the most efficient blockers of virus adsorption to Vero cells. J. Virol. 75:7769&#x2013;7773. 10.1128/JVI.75.16.7769-7773.2001</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.75.16.7769-7773.2001</ArticleId><ArticleId IdType="pmc">PMC115016</ArticleId><ArticleId IdType="pubmed">11462053</ArticleId></ArticleIdList></Reference><Reference><Citation>Pierson T, Fremont D, Kuhn R, Diamond M. 2008. Structural insights into the mechanisms of antibody-mediated neutralization of flavivirus infection: implications for vaccine development. Cell Host Microbe 4:229&#x2013;238. 10.1016/j.chom.2008.08.004</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chom.2008.08.004</ArticleId><ArticleId IdType="pmc">PMC2678546</ArticleId><ArticleId IdType="pubmed">18779049</ArticleId></ArticleIdList></Reference><Reference><Citation>Heinz F, Stiasny K. 2012. Flaviviruses and their antigenic structure. J. Clin. Virol. 55:289&#x2013;295. 10.1016/j.jcv.2012.08.024</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jcv.2012.08.024</ArticleId><ArticleId IdType="pubmed">22999801</ArticleId></ArticleIdList></Reference><Reference><Citation>Dejnirattisai W, Jumnainsong A, Onsirisakul N, Fitton P, Vasanawathana S, Limpitikul W, Puttikhunt C, Edwards C, Duangchinda T, Supasa S, Chawansuntati K, Malasit P, Mongkolsapaya J, Screaton G. 2010. Cross-reacting antibodies enhance dengue virus infection in humans. Science 328:745&#x2013;748. 10.1126/science.1185181</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1185181</ArticleId><ArticleId IdType="pmc">PMC3837288</ArticleId><ArticleId IdType="pubmed">20448183</ArticleId></ArticleIdList></Reference><Reference><Citation>Crill W, Hughes H, Delorey M, Chang G. 2009. Humoral immune responses of dengue fever patients using epitope-specific serotype-2 virus-like particle antigens. PLoS One 4:e4991. 10.1371/journal.pone.0004991</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0004991</ArticleId><ArticleId IdType="pmc">PMC2659788</ArticleId><ArticleId IdType="pubmed">19337372</ArticleId></ArticleIdList></Reference><Reference><Citation>Lai CY, Williams KL, Wu YC, Knight S, Balmaseda A, Harris E, Wang WK. 2013. Analysis of cross-reactive antibodies recognizing the fusion loop of envelope protein and correlation with neutralizing antibody titers in Nicaraguan dengue cases. PLoS Negl. Trop. Dis. 7:e2451. 10.1371/journal.pntd.0002451</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pntd.0002451</ArticleId><ArticleId IdType="pmc">PMC3777924</ArticleId><ArticleId IdType="pubmed">24069496</ArticleId></ArticleIdList></Reference><Reference><Citation>Heinz F, Stiasny K. 2012. Flaviviruses and flavivirus vaccines. Vaccine 30:4301&#x2013;4306. 10.1016/j.vaccine.2011.09.114</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2011.09.114</ArticleId><ArticleId IdType="pubmed">22682286</ArticleId></ArticleIdList></Reference><Reference><Citation>Sabchareon A, Wallace D, Sirivichayakul C, Limkittikul K, Chanthavanich P, Suvannadabba S, Jiwariyavej V, Dulyachai W, Pengsaa K, Wartel T, Moureau A, Saville M, Bouckenooghe A, Viviani S, Tornieporth N, Lang J. 2012. Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: a randomised, controlled phase 2b trial. Lancet 380:1559&#x2013;1567. 10.1016/S0140-6736(12)61428-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(12)61428-7</ArticleId><ArticleId IdType="pubmed">22975340</ArticleId></ArticleIdList></Reference><Reference><Citation>Robinson HL, Torres C. 1997. DNA vaccines. Semin. Immunol. 9:271&#x2013;283. 10.1006/smim.1997.0083</Citation><ArticleIdList><ArticleId IdType="doi">10.1006/smim.1997.0083</ArticleId><ArticleId IdType="pubmed">9327522</ArticleId></ArticleIdList></Reference><Reference><Citation>Shedlock D, Weiner D. 2000. DNA vaccination: antigen presentation and the induction of immunity. J. Leukoc. Biol. 68:793&#x2013;806. 10.1189/jlb.1938-3673</Citation><ArticleIdList><ArticleId IdType="doi">10.1189/jlb.1938-3673</ArticleId><ArticleId IdType="pubmed">11129646</ArticleId></ArticleIdList></Reference><Reference><Citation>Beckett CG, Tjaden J, Burgess T, Danko JR, Tamminga C, Simmons M, Wu SJ, Sun P, Kochel T, Raviprakash K, Hayes CG, Porter KR. 2011. Evaluation of a prototype dengue-1 DNA vaccine in a phase 1 clinical trial. Vaccine 29:960&#x2013;968. 10.1016/j.vaccine.2010.11.050</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2010.11.050</ArticleId><ArticleId IdType="pubmed">21111785</ArticleId></ArticleIdList></Reference><Reference><Citation>Yauch LE, Shresta S. 2014. Dengue virus vaccine development. Adv. Virus Res. 88:315&#x2013;372. 10.1016/B978-0-12-800098-4.00007-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/B978-0-12-800098-4.00007-6</ArticleId><ArticleId IdType="pubmed">24373316</ArticleId></ArticleIdList></Reference><Reference><Citation>Holmes EC, Twiddy SS. 2003. The origin, emergence and evolutionary genetics of dengue virus. Infect. Genet. Evol. 3:19&#x2013;28. 10.1016/S1567-1348(03)00004-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1567-1348(03)00004-2</ArticleId><ArticleId IdType="pubmed">12797969</ArticleId></ArticleIdList></Reference><Reference><Citation>Twiddy SS, Farrar JJ, Chau NV, Wills B, Gould EA, Gritsun T, Lloyd G, Holmes EC. 2002. Phylogenetic relationships and differential selection pressures among genotypes of dengue-2 virus. Virology 298:63&#x2013;72. 10.1006/viro.2002.1447</Citation><ArticleIdList><ArticleId IdType="doi">10.1006/viro.2002.1447</ArticleId><ArticleId IdType="pubmed">12093174</ArticleId></ArticleIdList></Reference><Reference><Citation>Barban V, Munoz-Jordan J, Santiago G, Mantel N, Girerd Y. 2012. Broad neutralization of wild-type dengue virus isolates following immunization in monkeys with a tetravalent dengue vaccine based on chimeric yellow fever 17D/dengue viruses. Virology 429:91&#x2013;98. 10.1016/j.virol.2012.03.007</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.virol.2012.03.007</ArticleId><ArticleId IdType="pubmed">22542002</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang X, Ge P, Yu X, Brannan J, Bi G, Zhang Q, Schein S, Zhou Z. 2013. Cryo-EM structure of the mature dengue virus at 3.5-&#x212b; resolution. Nat. Struct. Mol. Biol. 20:105&#x2013;110. 10.1038/nsmb.2463</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nsmb.2463</ArticleId><ArticleId IdType="pmc">PMC3593067</ArticleId><ArticleId IdType="pubmed">23241927</ArticleId></ArticleIdList></Reference><Reference><Citation>Li L, Lok SM, Yu IM, Zhang Y, Kuhn RJ, Chen J, Rossmann MG. 2008. The flavivirus precursor membrane-envelope protein complex: structure and maturation. Science 319:1830&#x2013;1834. 10.1126/science.1153263</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1153263</ArticleId><ArticleId IdType="pubmed">18369147</ArticleId></ArticleIdList></Reference><Reference><Citation>Modis Y, Ogata S, Clements D, Harrison SC. 2003. A ligand-binding pocket in the dengue virus envelope glycoprotein. Proc. Natl. Acad. Sci. U. S. A. 100:6986&#x2013;6991. 10.1073/pnas.0832193100</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0832193100</ArticleId><ArticleId IdType="pmc">PMC165817</ArticleId><ArticleId IdType="pubmed">12759475</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang G-JJ, Hunt AR, Holmes DA, Springfield T, Chiueh TS, Roehrig JT, Gubler DJ. 2003. Enhancing biosynthesis and secretion of premembrane and envelope proteins by the chimeric plasmid of dengue virus type 2 and Japanese encephalitis virus. Virology 306:170&#x2013;180. 10.1016/S0042-6822(02)00028-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0042-6822(02)00028-4</ArticleId><ArticleId IdType="pubmed">12620809</ArticleId></ArticleIdList></Reference><Reference><Citation>Hughes H, Crill W, Chang G. 2012. Manipulation of immunodominant dengue virus E protein epitopes reduces potential antibody-dependent enhancement. Virol. J. 9:115. 10.1186/1743-422X-9-115</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1743-422X-9-115</ArticleId><ArticleId IdType="pmc">PMC3424142</ArticleId><ArticleId IdType="pubmed">22709350</ArticleId></ArticleIdList></Reference><Reference><Citation>Crill WD, Hughes HR, Trainor NB, Davis BS, Whitney MT, Chang GJ. 2012. Sculpting humoral immunity through dengue vaccination to enhance protective immunity. Front. Immunol. 3:334. 10.3389/fimmu.2012.00334</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2012.00334</ArticleId><ArticleId IdType="pmc">PMC3492872</ArticleId><ArticleId IdType="pubmed">23162552</ArticleId></ArticleIdList></Reference><Reference><Citation>Engler C, Kandzia R, Marillonnet S. 2008. A one pot, one step, precision cloning method with high throughput capability. PLoS One 3:e3647. 10.1371/journal.pone.0003647</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0003647</ArticleId><ArticleId IdType="pmc">PMC2574415</ArticleId><ArticleId IdType="pubmed">18985154</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang G, Hunt A, Davis B. 2000. A single intramuscular injection of recombinant plasmid DNA induces protective immunity and prevents Japanese encephalitis in mice. J. Virol. 74:4244&#x2013;4252. 10.1128/JVI.74.9.4244-4252.2000</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.74.9.4244-4252.2000</ArticleId><ArticleId IdType="pmc">PMC111940</ArticleId><ArticleId IdType="pubmed">10756038</ArticleId></ArticleIdList></Reference><Reference><Citation>Sukupolvi-Petty S, Austin S, Engle M, Brien J, Dowd K, Williams K, Johnson S, Rico-Hesse R, Harris E, Pierson T, Fremont D, Diamond M. 2010. Structure and function analysis of therapeutic monoclonal antibodies against dengue virus type 2. J. Virol. 84:9227&#x2013;9239. 10.1128/JVI.01087-10</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.01087-10</ArticleId><ArticleId IdType="pmc">PMC2937608</ArticleId><ArticleId IdType="pubmed">20592088</ArticleId></ArticleIdList></Reference><Reference><Citation>Lok S, Ng M, Aaskov J. 2001. Amino acid and phenotypic changes in dengue 2 virus associated with escape from neutralisation by IgM antibody. J. Med. Virol. 65:315&#x2013;323. 10.1002/jmv.2036</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.2036</ArticleId><ArticleId IdType="pubmed">11536239</ArticleId></ArticleIdList></Reference><Reference><Citation>de Alwis R, Smith S, Olivarez N, Messer W, Huynh J, Wahala W, White L, Diamond M, Baric R, Crowe JJ, de Silva AM. 2012. Identification of human neutralizing antibodies that bind to complex epitopes on dengue virions. Proc. Natl. Acad. Sci. U. S. A. 109:7439&#x2013;7444. 10.1073/pnas.1200566109</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1200566109</ArticleId><ArticleId IdType="pmc">PMC3358852</ArticleId><ArticleId IdType="pubmed">22499787</ArticleId></ArticleIdList></Reference><Reference><Citation>Gromowski G, Barrett A. 2007. Characterization of an antigenic site that contains a dominant, type-specific neutralization determinant on the envelope protein domain III (ED3) of dengue 2 virus. Virology 366:349&#x2013;360. 10.1016/j.virol.2007.05.042</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.virol.2007.05.042</ArticleId><ArticleId IdType="pubmed">17719070</ArticleId></ArticleIdList></Reference><Reference><Citation>Bernardo L, Yndart A, Vazquez S, Morier L, Guzman MG. 2005. Antibody responses to Asian and American genotypes of dengue 2 virus in immunized mice. Clin. Diagn. Lab. Immunol. 12:361&#x2013;362. 10.1128/CDLI.12.2.361-362.2005</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/CDLI.12.2.361-362.2005</ArticleId><ArticleId IdType="pmc">PMC549307</ArticleId><ArticleId IdType="pubmed">15699435</ArticleId></ArticleIdList></Reference><Reference><Citation>Zulueta A, Martin J, Hermida L, Alvarez M, Valdes I, Prado I, Chinea G, Rosario D, Guillen G, Guzman MG. 2006. Amino acid changes in the recombinant dengue 3 envelope domain III determine its antigenicity and immunogenicity in mice. Virus Res. 121:65&#x2013;73. 10.1016/j.virusres.2006.04.003</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.virusres.2006.04.003</ArticleId><ArticleId IdType="pubmed">16781791</ArticleId></ArticleIdList></Reference><Reference><Citation>Aaskov JG, Geysen HM, Mason TJ. 1989. Serologically defined linear epitopes in the envelope protein of dengue 2 (Jamaica strain 1409). Arch. Virol. 105:209&#x2013;221. 10.1007/BF01311358</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/BF01311358</ArticleId><ArticleId IdType="pubmed">2473720</ArticleId></ArticleIdList></Reference><Reference><Citation>Roehrig JT, Bolin RA, Kelly RG. 1998. Monoclonal antibody mapping of the envelope glycoprotein of the dengue 2 virus, Jamaica. Virology 246:317&#x2013;328. 10.1006/viro.1998.9200</Citation><ArticleIdList><ArticleId IdType="doi">10.1006/viro.1998.9200</ArticleId><ArticleId IdType="pubmed">9657950</ArticleId></ArticleIdList></Reference><Reference><Citation>Gromowski G, Barrett N, Barrett A. 2008. Characterization of dengue virus complex-specific neutralizing epitopes on envelope protein domain III of dengue 2 virus. J. Virol. 82:8828&#x2013;8837. 10.1128/JVI.00606-08</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.00606-08</ArticleId><ArticleId IdType="pmc">PMC2519678</ArticleId><ArticleId IdType="pubmed">18562544</ArticleId></ArticleIdList></Reference><Reference><Citation>Henchal EA, McCown JM, Burke DS, Seguin MC, Brandt WE. 1985. Epitopic analysis of antigenic determinants on the surface of dengue 2 virions using monoclonal antibodies. Am. J. Trop. Med. Hyg. 34:162&#x2013;169</Citation><ArticleIdList><ArticleId IdType="pubmed">2578750</ArticleId></ArticleIdList></Reference><Reference><Citation>Webster D, Farrar J, Rowland-Jones S. 2009. Progress towards a dengue vaccine. Lancet Infect. Dis. 9:678&#x2013;687. 10.1016/S1473-3099(09)70254-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(09)70254-3</ArticleId><ArticleId IdType="pubmed">19850226</ArticleId></ArticleIdList></Reference><Reference><Citation>Men RH, Bray M, Lai CJ. 1991. Carboxy-terminally truncated dengue virus envelope glycoproteins expressed on the cell surface and secreted extracellularly exhibit increased immunogenicity in mice. J. Virol. 65:1400&#x2013;1407</Citation><ArticleIdList><ArticleId IdType="pmc">PMC239918</ArticleId><ArticleId IdType="pubmed">1995950</ArticleId></ArticleIdList></Reference><Reference><Citation>Kyle J, Balsitis S, Zhang L, Beatty P, Harris E. 2008. Antibodies play a greater role than immune cells in heterologous protection against secondary dengue virus infection in a mouse model. Virology 380:296&#x2013;303. 10.1016/j.virol.2008.08.008</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.virol.2008.08.008</ArticleId><ArticleId IdType="pmc">PMC2590773</ArticleId><ArticleId IdType="pubmed">18774583</ArticleId></ArticleIdList></Reference><Reference><Citation>Endy T, Nisalak A, Chunsuttitwat S, Vaughn DW, Green S, Ennis FA, Rothman AL, Libraty DH. 2004. Relationship of preexisting dengue virus (DV) neutralizing antibody levels to viremia and severity of disease in a prospective cohort study of DV infection in Thailand. J. Infect. Dis. 189:990&#x2013;1000. 10.1086/382280</Citation><ArticleIdList><ArticleId IdType="doi">10.1086/382280</ArticleId><ArticleId IdType="pubmed">14999601</ArticleId></ArticleIdList></Reference><Reference><Citation>Jan LR, Yang CS, Henchal LS, Sumiyoshi H, Summers PL, Dubois DR, Lai CJ. 1993. Increased immunogenicity and protective efficacy in outbred and inbred mice by strategic carboxyl-terminal truncation of Japanese encephalitis virus envelope glycoprotein. Am. J. Trop. Med. Hyg. 48:412&#x2013;423</Citation><ArticleIdList><ArticleId IdType="pubmed">8385887</ArticleId></ArticleIdList></Reference><Reference><Citation>Christian EA, Kahle KM, Mattia K, Puffer BA, Pfaff JM, Miller A, Paes C, Davidson E, Doranz BJ. 2013. Atomic-level functional model of dengue virus envelope protein infectivity. Proc. Natl. Acad. Sci. U. S. A. 110:18662&#x2013;18667. 10.1073/pnas.1310962110</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1310962110</ArticleId><ArticleId IdType="pmc">PMC3831943</ArticleId><ArticleId IdType="pubmed">24158478</ArticleId></ArticleIdList></Reference><Reference><Citation>Blaney JE, Matro JM, Murphy BR, Whitehead SS. 2005. Recombinant, live-attenuated tetravalent dengue virus vaccine formulations induce a balanced, broad, and protective neutralizing antibody response against each of the four serotypes in rhesus monkeys. J. Virol. 79:5516&#x2013;5528. 10.1128/JVI.79.9.5516-5528.2005</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.79.9.5516-5528.2005</ArticleId><ArticleId IdType="pmc">PMC1082773</ArticleId><ArticleId IdType="pubmed">15827166</ArticleId></ArticleIdList></Reference><Reference><Citation>Shrestha B, Brien JD, Sukupolvi-Petty S, Austin SK, Edeling MA, Kim T, O'Brien KM, Nelson CA, Johnson S, Fremont DH, Diamond MS. 2010. The development of therapeutic antibodies that neutralize homologous and heterologous genotypes of denguevirus type 1. PLoS Pathog. 6:e1000823. 10.1371/journal.ppat.1000823</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.ppat.1000823</ArticleId><ArticleId IdType="pmc">PMC2848552</ArticleId><ArticleId IdType="pubmed">20369024</ArticleId></ArticleIdList></Reference><Reference><Citation>Brien JD, Austin SK, Sukupolvi-Petty S, O'Brien KM, Johnson S, Fremont DH, Diamond MS. 2010. Genotype-specific neutralization and protection by antibodies against dengue virus type 3. J. Virol. 84:10630&#x2013;10643. 10.1128/JVI.01190-10</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.01190-10</ArticleId><ArticleId IdType="pmc">PMC2950583</ArticleId><ArticleId IdType="pubmed">20702644</ArticleId></ArticleIdList></Reference><Reference><Citation>Wahala WM, Donaldson EF, de Alwis R, Accavitti-Loper MA, Baric RS, de Silva AM. 2010. Natural strain variation and antibody neutralization of dengue serotype 3 viruses. PLoS Pathog. 6:e1000821. 10.1371/journal.ppat.1000821</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.ppat.1000821</ArticleId><ArticleId IdType="pmc">PMC2841629</ArticleId><ArticleId IdType="pubmed">20333252</ArticleId></ArticleIdList></Reference><Reference><Citation>Sukupolvi-Petty S, Brien JD, Austin SK, Shrestha B, Swayne S, Kahle K, Doranz BJ, Johnson S, Pierson TC, Fremont DH, Diamond MS. 2013. Functional analysis of antibodies against dengue virus type 4 reveals strain-dependent epitope exposure that impacts neutralization and protection. J. Virol. 87:8826&#x2013;8842. 10.1128/JVI.01314-13</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.01314-13</ArticleId><ArticleId IdType="pmc">PMC3754038</ArticleId><ArticleId IdType="pubmed">23785205</ArticleId></ArticleIdList></Reference><Reference><Citation>Pitcher TJ, Gromowski GD, Beasley DW, Barrett AD. 2012. Conservation of the DENV-2 type-specific and DEN complex-reactive antigenic sites among DENV-2 genotypes. Virology 422:386&#x2013;392. 10.1016/j.virol.2011.10.020</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.virol.2011.10.020</ArticleId><ArticleId IdType="pmc">PMC4142575</ArticleId><ArticleId IdType="pubmed">22153298</ArticleId></ArticleIdList></Reference><Reference><Citation>Beltramello M, Williams KL, Simmons CP, Macagno A, Simonelli L, Quyen NT, Sukupolvi-Petty S, Navarro-Sanchez E, Young PR, de Silva AM, Rey FA, Varani L, Whitehead SS, Diamond MS, Harris E, Lanzavecchia A, Sallusto F. 2010. The human immune response to dengue virus is dominated by highly cross-reactive antibodies endowed with neutralizing and enhancing activity. Cell Host Microbe 8:271&#x2013;283. 10.1016/j.chom.2010.08.007</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chom.2010.08.007</ArticleId><ArticleId IdType="pmc">PMC3884547</ArticleId><ArticleId IdType="pubmed">20833378</ArticleId></ArticleIdList></Reference><Reference><Citation>Azevedo A, Yamamura A, Freire M, Trindade G, Bonaldo M, Galler R, Alves A. 2011. DNA vaccines against dengue virus type 2 based on truncate envelope protein or its domain III. PLoS One 6:e20528. 10.1371/journal.pone.0020528</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0020528</ArticleId><ArticleId IdType="pmc">PMC3136928</ArticleId><ArticleId IdType="pubmed">21779317</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsai WY, Lai CY, Wu YC, Lin HE, Edwards C, Jumnainsong A, Kliks S, Halstead S, Mongkolsapaya J, Screaton GR, Wang WK. 2013. High-avidity and potently neutralizing cross-reactive human monoclonal antibodies derived from secondary dengue virus infection. J. Virol. 87:12562&#x2013;12575. 10.1128/JVI.00871-13</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.00871-13</ArticleId><ArticleId IdType="pmc">PMC3838129</ArticleId><ArticleId IdType="pubmed">24027331</ArticleId></ArticleIdList></Reference><Reference><Citation>Sukupolvi-Petty S, Austin SK, Purtha WE, Oliphant T, Nybakken GE, Schlesinger JJ, Roehrig JT, Gromowski GD, Barrett AD, Fremont DH, Diamond MS. 2007. Type- and subcomplex-specific neutralizing antibodies against domain III of dengue virus type 2 envelope protein recognize adjacent epitopes. J. Virol. 81:12816&#x2013;12826. 10.1128/JVI.00432-07</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.00432-07</ArticleId><ArticleId IdType="pmc">PMC2169112</ArticleId><ArticleId IdType="pubmed">17881453</ArticleId></ArticleIdList></Reference><Reference><Citation>Wahala WM, Kraus AA, Haymore LB, Accavitti-Loper MA, de Silva AM. 2009. Dengue virus neutralization by human immune sera: role of envelope protein domain III-reactive antibody. Virology 392:103&#x2013;113. 10.1016/j.virol.2009.06.037</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.virol.2009.06.037</ArticleId><ArticleId IdType="pmc">PMC2746956</ArticleId><ArticleId IdType="pubmed">19631955</ArticleId></ArticleIdList></Reference><Reference><Citation>Williams KL, Wahala WM, Orozco S, de Silva AM, Harris E. 2012. Antibodies targeting dengue virus envelope domain III are not required for serotype-specific protection or prevention of enhancement in vivo. Virology 429:12&#x2013;20. 10.1016/j.virol.2012.03.003</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.virol.2012.03.003</ArticleId><ArticleId IdType="pmc">PMC3683589</ArticleId><ArticleId IdType="pubmed">22537810</ArticleId></ArticleIdList></Reference><Reference><Citation>Teoh E, Kukkaro P, Teo E, Lim A, Tan T, Yip A, Schul W, Aung M, Kostyuchenko V, Leo Y, Chan S, Smith K, Chan A, Zou G, Ooi E, Kemeny D, Tan G, Ng J, Ng M, Alonso S, Fisher D, Shi P, Hanson B, Lok S, MacAry P. 2012. The structural basis for serotype-specific neutralization of dengue virus by a human antibody. Sci. Transl. Med. 4:139&#x2013;183. 10.1126/scitranslmed.3003888</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.3003888</ArticleId><ArticleId IdType="pubmed">22723463</ArticleId></ArticleIdList></Reference><Reference><Citation>Fibriansah G, Tan JL, Smith SA, de Alwis AR, Ng TS, Kostyuchenko VA, Ibarra KD, Wang J, Harris E, de Silva A, Crowe JE, Jr, Lok SM. 2014. A potent anti-dengue human antibody preferentially recognizes the conformation of E protein monomers assembled on the virus surface. EMBO Mol. Med. 6:358&#x2013;371. 10.1002/emmm.201303404</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/emmm.201303404</ArticleId><ArticleId IdType="pmc">PMC3958310</ArticleId><ArticleId IdType="pubmed">24421336</ArticleId></ArticleIdList></Reference><Reference><Citation>Goncalvez AP, Men R, Wernly C, Purcell RH, Lai CJ. 2004. Chimpanzee Fab fragments and a derived humanized immunoglobulin G1 antibody that efficiently cross-neutralize dengue type 1 and type 2 viruses. J. Virol. 78:12910&#x2013;12918. 10.1128/JVI.78.23.12910-12918.2004</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.78.23.12910-12918.2004</ArticleId><ArticleId IdType="pmc">PMC525007</ArticleId><ArticleId IdType="pubmed">15542643</ArticleId></ArticleIdList></Reference><Reference><Citation>Cockburn JJ, Navarro Sanchez ME, Goncalvez AP, Zaitseva E, Stura EA, Kikuti CM, Duquerroy S, Dussart P, Chernomordik LV, Lai CJ, Rey FA. 2012. Structural insights into the neutralization mechanism of a higher primate antibody against dengue virus. EMBO J. 31:767&#x2013;779. 10.1038/emboj.2011.439</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/emboj.2011.439</ArticleId><ArticleId IdType="pmc">PMC3273384</ArticleId><ArticleId IdType="pubmed">22139356</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaufmann B, Vogt MR, Goudsmit J, Holdaway HA, Aksyuk AA, Chipman PR, Kuhn RJ, Diamond MS, Rossmann MG. 2010. Neutralization of West Nile virus by cross-linking of its surface proteins with Fab fragments of the human monoclonal antibody CR4354. Proc. Natl. Acad. Sci. U. S. A. 107:18950&#x2013;18955. 10.1073/pnas.1011036107</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1011036107</ArticleId><ArticleId IdType="pmc">PMC2973864</ArticleId><ArticleId IdType="pubmed">20956322</ArticleId></ArticleIdList></Reference><Reference><Citation>Guy B, Barrere B, Malinowski C, Saville M, Teyssou R, Lang J. 2011. From research to phase III: preclinical, industrial and clinical development of the Sanofi Pasteur tetravalent dengue vaccine. Vaccine 29:7229&#x2013;7241. 10.1016/j.vaccine.2011.06.094</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2011.06.094</ArticleId><ArticleId IdType="pubmed">21745521</ArticleId></ArticleIdList></Reference><Reference><Citation>Vasilakis N, Shell E, Fokam E, Mason P, Hanley K, Estes D, Weaver S. 2007. Potential of ancestral sylvatic dengue-2 viruses to re-emerge. Virology 358:402&#x2013;412. 10.1016/j.virol.2006.08.049</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.virol.2006.08.049</ArticleId><ArticleId IdType="pmc">PMC3608925</ArticleId><ArticleId IdType="pubmed">17014880</ArticleId></ArticleIdList></Reference><Reference><Citation>Vasilakis N, Cardosa J, Hanley K, Holmes E, Weaver S. 2011. Fever from the forest: prospects for the continued emergence of sylvatic dengue virus and its impact on public health. Nat. Rev. Microbiol. 9:532&#x2013;541. 10.1038/nrmicro2595</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrmicro2595</ArticleId><ArticleId IdType="pmc">PMC3321645</ArticleId><ArticleId IdType="pubmed">21666708</ArticleId></ArticleIdList></Reference><Reference><Citation>Durbin A, Mayer S, Rossi S, Amaya-Larios I, Ramos-Castaneda J, Eong Ooi E, Jane Cardosa M, Munoz-Jordan J, Tesh R, Messer W, Weaver S, Vasilakis N. 2013. Emergence potential of sylvatic dengue virus type 4 in the urban transmission cycle is restrained by vaccination and homotypic immunity. Virology 439:34&#x2013;41. 10.1016/j.virol.2013.01.018</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.virol.2013.01.018</ArticleId><ArticleId IdType="pmc">PMC3622939</ArticleId><ArticleId IdType="pubmed">23485373</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferlenghi I, Clarke M, Ruttan T, Allison SL, Schalich J, Heinz FX, Harrison SC, Rey FA, Fuller SD. 2001. Molecular organization of a recombinant subviral particle from tick-borne encephalitis virus. Mol. Cell 7:593&#x2013;602. 10.1016/S1097-2765(01)00206-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1097-2765(01)00206-4</ArticleId><ArticleId IdType="pubmed">11463384</ArticleId></ArticleIdList></Reference><Reference><Citation>Lorenz IC, Kartenbeck J, Mezzacasa A, Allison SL, Heinz FX, Helenius A. 2003. Intracellular assembly and secretion of recombinant subviral particles from tick-borne encephalitis virus. J. Virol. 77:4370&#x2013;4382. 10.1128/JVI.77.7.4370-4382.2003</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.77.7.4370-4382.2003</ArticleId><ArticleId IdType="pmc">PMC150630</ArticleId><ArticleId IdType="pubmed">12634393</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>